Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Cross-scale cooperation enables sustainable use of a common-pool resource.

Ringsmuth AK, Lade SJ, Schlüter M.

Proc Biol Sci. 2019 Oct 23;286(1913):20191943. doi: 10.1098/rspb.2019.1943. Epub 2019 Oct 23.

PMID:
31640507
2.

Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome.

Gao C, McCormack C, van der Weyden C, Goh MS, Campbell BA, Twigger R, Buelens O, Harrison SJ, Khoo C, Lade S, Prince HM.

Blood. 2019 Oct 17;134(16):1346-1350. doi: 10.1182/blood.2019000765.

PMID:
31467061
3.

Increasing rates of SSA/P detection in a large open-access Australian colonoscopy cohort.

Nalankilli K, Huynh XT, Lade S, Stephens M, Hewett R, Moss A.

Endosc Int Open. 2019 Mar;7(3):E310-E316. doi: 10.1055/a-0808-3523. Epub 2019 Feb 28.

4.

Rare T-Cell Subtypes.

van der Weyden C, McCormack C, Lade S, Johnstone RW, Prince HM.

Cancer Treat Res. 2019;176:195-224. doi: 10.1007/978-3-319-99716-2_10.

PMID:
30596220
5.

Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma.

Blombery P, Thompson E, Ryland GL, Joyce R, Byrne DJ, Khoo C, Lade S, Hertzberg M, Hapgood G, Marlton P, Deva A, Lindeman G, Fox S, Westerman D, Prince M.

Oncotarget. 2018 Nov 16;9(90):36126-36136. doi: 10.18632/oncotarget.26308. eCollection 2018 Nov 16.

6.

Trajectories of the Earth System in the Anthropocene.

Steffen W, Rockström J, Richardson K, Lenton TM, Folke C, Liverman D, Summerhayes CP, Barnosky AD, Cornell SE, Crucifix M, Donges JF, Fetzer I, Lade SJ, Scheffer M, Winkelmann R, Schellnhuber HJ.

Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):8252-8259. doi: 10.1073/pnas.1810141115. Epub 2018 Aug 6.

7.

Host-specific proteomic and growth analysis of maize and tomato seedlings inoculated with Azospirillum brasilense Sp7.

Lade SB, Román C, Cueto-Ginzo AI, Serrano L, Sin E, Achón MA, Medina V.

Plant Physiol Biochem. 2018 Aug;129:381-393. doi: 10.1016/j.plaphy.2018.06.024. Epub 2018 Jun 19.

PMID:
29945074
8.

When optimization for governing human-environment tipping elements is neither sustainable nor safe.

Barfuss W, Donges JF, Lade SJ, Kurths J.

Nat Commun. 2018 Jun 15;9(1):2354. doi: 10.1038/s41467-018-04738-z.

9.

Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.

Fox LC, Yannakou CK, Ryland G, Lade S, Dickinson M, Campbell BA, Prince HM.

Int J Mol Sci. 2018 Jun 13;19(6). pii: E1758. doi: 10.3390/ijms19061758.

10.

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW.

N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.

11.

Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer.

Pattison S, Mitchell C, Lade S, Leong T, Busuttil RA, Boussioutas A.

PLoS One. 2017 Sep 18;12(9):e0183891. doi: 10.1371/journal.pone.0183891. eCollection 2017.

12.

Resilience offers escape from trapped thinking on poverty alleviation.

Lade SJ, Haider LJ, Engström G, Schlüter M.

Sci Adv. 2017 May 3;3(5):e1603043. doi: 10.1126/sciadv.1603043. eCollection 2017 May. Review.

13.

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.

Anderson MA, Tam C, Lew TE, Juneja S, Juneja M, Westerman D, Wall M, Lade S, Gorelik A, Huang DCS, Seymour JF, Roberts AW.

Blood. 2017 Jun 22;129(25):3362-3370. doi: 10.1182/blood-2017-01-763003. Epub 2017 May 4.

PMID:
28473407
14.

Obesity in pediatric kidney transplant recipients and the risks of acute rejection, graft loss and death.

Ladhani M, Lade S, Alexander SI, Baur LA, Clayton PA, McDonald S, Craig JC, Wong G.

Pediatr Nephrol. 2017 Aug;32(8):1443-1450. doi: 10.1007/s00467-017-3636-1. Epub 2017 Mar 30.

PMID:
28361229
15.

A novel process for the production of high-purity galactooligosaccharides (GOS) using consortium of microbes.

Saravanan R, Shubethar S, Narayanan S, Jain M, Lade S, Jadhav D, Maheswaran P, Avalakki UK, Dubey AK.

Prep Biochem Biotechnol. 2017 Mar 16;47(3):245-253. doi: 10.1080/10826068.2016.1207082. Epub 2016 Aug 15.

PMID:
27715472
16.

Patterns of CRISPR/Cas9 activity in plants, animals and microbes.

Bortesi L, Zhu C, Zischewski J, Perez L, Bassié L, Nadi R, Forni G, Lade SB, Soto E, Jin X, Medina V, Villorbina G, Muñoz P, Farré G, Fischer R, Twyman RM, Capell T, Christou P, Schillberg S.

Plant Biotechnol J. 2016 Dec;14(12):2203-2216. doi: 10.1111/pbi.12634. Epub 2016 Oct 11. Review.

17.

Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement.

Chan KL, van der Weyden C, Khoo C, Lade S, Blombery P, Westerman D, Khot A, Melo B, Johnstone RW, Prince HM, Dickinson M.

Leuk Lymphoma. 2017 Apr;58(4):996-998. doi: 10.1080/10428194.2016.1222375. Epub 2016 Aug 25. No abstract available.

PMID:
27558082
18.

Update and new approaches in the treatment of Castleman disease.

Chan KL, Lade S, Prince HM, Harrison SJ.

J Blood Med. 2016 Aug 3;7:145-58. doi: 10.2147/JBM.S60514. eCollection 2016. Review.

19.

Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma.

Blombery P, Thompson ER, Jones K, Arnau GM, Lade S, Markham JF, Li J, Deva A, Johnstone RW, Khot A, Prince HM, Westerman D.

Haematologica. 2016 Sep;101(9):e387-90. doi: 10.3324/haematol.2016.146118. Epub 2016 May 19. No abstract available.

20.

Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.

Chan KL, Blombery P, Jones K, Lade S, Carney D, Tran H, Seymour JF, Tam CS.

Br J Haematol. 2017 Apr;177(2):324-328. doi: 10.1111/bjh.14062. Epub 2016 May 15. No abstract available.

PMID:
27196127
21.

Bacterial Biofilm Infection Detected in Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

Hu H, Johani K, Almatroudi A, Vickery K, Van Natta B, Kadin ME, Brody G, Clemens M, Cheah CY, Lade S, Joshi PA, Prince HM, Deva AK.

Plast Reconstr Surg. 2016 Jun;137(6):1659-69. doi: 10.1097/PRS.0000000000002010.

PMID:
26890506
22.

Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, Di Napoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN.

J Clin Oncol. 2016 Jan 10;34(2):160-8. doi: 10.1200/JCO.2015.63.3412. Epub 2015 Nov 30. Erratum in: J Clin Oncol. 2016 Mar 10;34(8):888. DiNapoli, Arianna [corrected to Di Napoli, Arianna].

23.

Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases.

Agarwal R, Lade S, Liew D, Rogers TM, Byrne D, Feleppa F, Juneja S, Westerman DA.

J Clin Pathol. 2016 Mar;69(3):266-70. doi: 10.1136/jclinpath-2015-203002. Epub 2015 Aug 25.

PMID:
26307073
24.

An empirical model of the Baltic Sea reveals the importance of social dynamics for ecological regime shifts.

Lade SJ, Niiranen S, Hentati-Sundberg J, Blenckner T, Boonstra WJ, Orach K, Quaas MF, Österblom H, Schlüter M.

Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):11120-5. doi: 10.1073/pnas.1504954112. Epub 2015 Aug 17.

25.

Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.

Hughes CF, Newland K, McCormack C, Lade S, Prince HM.

Australas J Dermatol. 2016 Aug;57(3):182-91. doi: 10.1111/ajd.12349. Epub 2015 May 18. Review.

PMID:
25988337
26.

The efficacy of methotrexate for lymphomatoid papulosis.

Newland KM, McCormack CJ, Twigger R, Buelens O, Hughes CF, Lade S, Dickinson M, Yap LM, Ryan G, Prince HM.

J Am Acad Dermatol. 2015 Jun;72(6):1088-90. doi: 10.1016/j.jaad.2015.03.001. No abstract available. Erratum in: J Am Acad Dermatol. 2015 Sep;73(3):532.

PMID:
25981010
27.

Fusion leads to effective segregation of damage during cell division: An analytical treatment.

Lade SJ, Coelho M, Tolić IM, Gross T.

J Theor Biol. 2015 Aug 7;378:47-55. doi: 10.1016/j.jtbi.2015.04.022. Epub 2015 Apr 28.

PMID:
25934351
28.

The developmental examination.

Lade S, Peacock K.

J Paediatr Child Health. 2015 Mar;51(3):243-4. doi: 10.1111/jpc.12855. No abstract available.

PMID:
25758305
29.

Predictors of outcome after surgery for gastric cancer in a Western cohort.

Pattison S, Mann GB, Crosthwaite G, Lade S, Mitchell C, Leong T, Busuttil RA, Boussioutas A.

ANZ J Surg. 2016 Jun;86(6):469-74. doi: 10.1111/ans.12915. Epub 2014 Nov 12.

PMID:
25388659
30.

Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy.

Hughes CF, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, Buelens O, Newland K, Tam C, Dickinson M, Ryan G, Ritchie D, Wood C, Prince HM.

Blood. 2015 Jan 1;125(1):71-81. doi: 10.1182/blood-2014-07-588236. Epub 2014 Oct 21.

PMID:
25336628
31.

Cutaneous CD30 positive lymphoproliferative disorders with coexistent epithelial neoplasms: Report of two cases.

Newland KM, McCormack CJ, Prince HM, Lade S.

Australas J Dermatol. 2015 Nov;56(4):e83-7. doi: 10.1111/ajd.12180. Epub 2014 Oct 21.

PMID:
25330922
32.

Fusion of protein aggregates facilitates asymmetric damage segregation.

Coelho M, Lade SJ, Alberti S, Gross T, Tolić IM.

PLoS Biol. 2014 Jun 17;12(6):e1001886. doi: 10.1371/journal.pbio.1001886. eCollection 2014 Jun.

33.

A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal response.

Busuttil RA, George J, Tothill RW, Ioculano K, Kowalczyk A, Mitchell C, Lade S, Tan P, Haviv I, Boussioutas A.

Clin Cancer Res. 2014 May 15;20(10):2761-72. doi: 10.1158/1078-0432.CCR-13-3049. Epub 2014 Mar 21.

34.

IgG4-related disease with cutaneous manifestations treated with rituximab: case report and literature review.

Jalilian C, Prince HM, McCormack C, Lade S, Cheah CY.

Australas J Dermatol. 2014 May;55(2):132-6. doi: 10.1111/ajd.12100. Epub 2013 Sep 5. Review.

PMID:
24032760
35.

High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma.

Kashyap R, Lau E, George A, Seymour JF, Lade S, Hicks RJ, Hofman MS.

Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1330-6. doi: 10.1007/s00259-013-2429-4. Epub 2013 May 8.

PMID:
23653244
36.

Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks.

Song J, Jones LM, Chavarria GE, Charlton-Sevcik AK, Jantz A, Johansen A, Bayeh L, Soeung V, Snyder LK, Lade SD Jr, Chaplin DJ, Trawick ML, Pinney KG.

Bioorg Med Chem Lett. 2013 May 1;23(9):2801-7. doi: 10.1016/j.bmcl.2012.12.025. Epub 2012 Dec 20.

PMID:
23540644
37.

Erdheim-Chester disease harboring the BRAF V600E mutation.

Blombery P, Wong SQ, Lade S, Prince HM.

J Clin Oncol. 2012 Nov 10;30(32):e331-2. doi: 10.1200/JCO.2012.43.2260. Epub 2012 Sep 24. No abstract available.

PMID:
23008323
38.

Complete remission of localised gastric plasmacytomas following definitive radiotherapy.

Tan J, Lade S, Harrison S, Opat S, Mac Manus MP.

J Med Imaging Radiat Oncol. 2012 Jun;56(3):328-31. doi: 10.1111/j.1754-9485.2012.02369.x. Epub 2012 Apr 10.

PMID:
22697332
39.

Early warning signals for critical transitions: a generalized modeling approach.

Lade SJ, Gross T.

PLoS Comput Biol. 2012 Feb;8(2):e1002360. doi: 10.1371/journal.pcbi.1002360. Epub 2012 Feb 2.

40.

(E)-3-(Furan-2-yl)-1-(4-meth-oxy-phen-yl)prop-2-en-1-one.

Kapoor K, Gupta VK, Kant R, Pandya JR, Lade SB, Joshi HS.

Acta Crystallogr Sect E Struct Rep Online. 2011 Dec 1;67(Pt 12):o3185. doi: 10.1107/S160053681104373X. Epub 2011 Nov 5.

41.

Effectiveness of beads for tracking small-scale molecular motor dynamics.

Lade SJ, Craig EM, Linke H.

Phys Rev E Stat Nonlin Soft Matter Phys. 2011 Aug;84(2 Pt 1):021907. Epub 2011 Aug 5.

PMID:
21929020
42.

Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity.

Lechner MG, Lade S, Liebertz DJ, Prince HM, Brody GS, Webster HR, Epstein AL.

Cancer. 2011 Apr 1;117(7):1478-89. doi: 10.1002/cncr.25654. Epub 2010 Nov 8.

43.

Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity.

Thompson PA, Lade S, Webster H, Ryan G, Prince HM.

Haematologica. 2010 Nov;95(11):1977-9. doi: 10.3324/haematol.2010.026237. Epub 2010 Aug 26. Review. No abstract available.

44.

Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient.

Law AB, Ryan G, Lade S, Prince HM.

Int J Hematol. 2010 Mar;91(2):347-8; author reply 349. doi: 10.1007/s12185-010-0497-9. Epub 2010 Feb 10. No abstract available.

PMID:
20146033
45.

Geometric and projection effects in Kramers-Moyal analysis.

Lade SJ.

Phys Rev E Stat Nonlin Soft Matter Phys. 2009 Sep;80(3 Pt 1):031137. Epub 2009 Sep 24.

PMID:
19905092
46.

IgA nephropathy associated with cutaneous T cell lymphoma.

Bajel A, Yin Lin M, Hill PA, Goodman D, McCormack C, Foley P, Davison J, Hönemann D, Kenealy M, Lade S, Ryan G, Prince HM.

Leuk Lymphoma. 2009 Dec;50(12):2083-5. doi: 10.3109/10428190903288472. No abstract available.

PMID:
19863174
47.

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE.

J Clin Oncol. 2009 Nov 10;27(32):5410-7. doi: 10.1200/JCO.2008.21.6150. Epub 2009 Oct 13.

48.

Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.

Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, Chiew YE, Traficante N, Fereday S, Johnson D, Fox S, Sellers W, Urashima M, Salvesen HB, Meyerson M, Bowtell D; AOCS Study Group.

Clin Cancer Res. 2009 Feb 15;15(4):1417-27. doi: 10.1158/1078-0432.CCR-08-1564. Epub 2009 Feb 3.

49.

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.

Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell DD.

Clin Cancer Res. 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196.

50.

Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol.

Arulogun S, Prince HM, Gambell P, Lade S, Ryan G, Eaton E, McCormack C.

J Am Acad Dermatol. 2008 Oct;59(4):589-95. doi: 10.1016/j.jaad.2008.05.038. Epub 2008 Jul 24.

PMID:
18656282

Supplemental Content

Support Center